 Nuwellis

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Nuwellis reports revenue growth and margin improvement in Q1 2024

Nuwellis' Q1 2024 performance showed revenue growth driven by consumable utilization, improved margins, and reduced operating losses. Challenges in critical care revenue persist, but expense reductions and growth opportunities in pediatrics signal a positive outlook.

Nuwellis reports revenue growth and operational improvements in Q2 2024

Nuwellis (NUWE) showed improved financial performance in Q2 2024 with revenue growth and reduced operating loss, despite challenges in the pediatric segment.
The company's strengths lie in successful product launches, financial stability, and increasing market presence, while facing challenges in pediatric revenue and R&D expenses.
Opportunities for Nuwellis include leveraging positive momentum, expanding product adoption, and capitalizing on its strong financial position for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don't respond to diuretics Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don't respond to diuretics

New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies

Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Nuwellis, Inc. (NUWE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Nuwellis, Inc. (NUWE) Is a Great 'Buy the Bottom' Stock Now

Nuwellis, Inc. (NASDAQ:NUWE ) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO John Jefferies - Chief Medical Officer Rob Scott - CFO Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Anthony Vendetti - Maxim Group Operator Good day, and welcome to the Nuwellis third-quarter 2023 earnings conference call. [Operator Instructions].

Nuwellis, Inc. (NUWE) Q3 2023 Earnings Call Transcript

MINNEAPOLIS, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2023.

Nuwellis, Inc. Announces Third Quarter 2023 Financial Results

MINNEAPOLIS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.

Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023

MINNEAPOLIS, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the closing of its previously announced public offering of 150,000 units (the “Units”), with each Unit consisting of one share of the Company's Series J Convertible Redeemable Preferred Stock, par value $0.0001 per share, with a liquidation preference of $25.00 per share (the “Series J Convertible Preferred Stock”), and one warrant (the “Warrants”) to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock.

Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

MINNEAPOLIS, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the pricing of a public offering of 150,000 units (the “Units”), with each Unit consisting of one share of the Company's Series J Convertible Redeemable Preferred Stock, par value $0.0001 per share, with a liquidation preference of $25.00 per share (the “Series J Convertible Preferred Stock”), and one warrant (the “Warrants”) to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock. The offering is expected to close on October 17, 2023, subject to customary closing conditions.

Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

MINNEAPOLIS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (Nuwellis), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that its distribution partner, SeaStar Medical (SeaStar), received correspondence from the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) indicating that the Agency considers SeaStar's Selective Cytopheretic Device (SCD) Pediatric (SCD-PED) to be approvable under a Humanitarian Device Exemption (HDE) for use in children weighing 10 kilograms or more with acute kidney injury (AKI) and sepsis or a septic condition requiring continuous kidney replacement therapy (CKRT) in the hospital intensive care unit (ICU).

Nuwellis Provides Regulatory Update on SeaStar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption

MINNEAPOLIS, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that President and Chief Executive Officer Nestor Jaramillo, Chief Financial Officer Rob Scott, and Chief Medical Officer Dr. John Jefferies, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 12:00 pm ET.

Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase

Nuwellis (NASDAQ: NUWE ) stock is taking a beating on Monday despite a lack of news concerning the medical device company. In fact, there's really not much in the way of anything to report about Nuwellis stock today.

Why Is Nuwellis (NUWE) Stock Down Today?

Nuwellis, Inc. (NASDAQ:NUWE ) Q2 2023 Earnings Conference Call August 8, 2023 9:00 AM ET Company Participants Vivian Cervantes - Investor Relations Nestor Jaramillo - President & Chief Executive Officer John Jefferies - Chief Medical Officer Lynn Blake - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Anthony Vendetti - Maxim Group Brooks O'Neil - Lake Street Capital Markets Operator Good morning, and welcome to the Nuwellis Inc Second Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.

Nuwellis, Inc. (NUWE) Q2 2023 Earnings Call Transcript

MINNEAPOLIS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the second quarter ended June 30, 2023.

Nuwellis, Inc. Announces Second Quarter 2023 Financial Results

MINNEAPOLIS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, announced today that Lynn Blake will be transitioning from her role as Chief Financial Officer to pursue broader career goals. To ensure a smooth transition, Ms. Blake has agreed to remain in her current role through September 1, 2023 and then consult with the Company through March 31, 2024.

Nuwellis Announces Plan for CFO Transition

MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its second quarter 2023 financial results will be released on Tuesday, August 8, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.

Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023

MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo, President and Chief Executive Officer, and Lynn Blake, Chief Financial Officer, will participate in a fireside chat at the Maxim Group Virtual Healthcare Conference on June 21, 2023 at 12:00 PM ET.

Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference

MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of patients suffering from fluid overload, today announced that Mike McCormick has been appointed to the company's Board of Directors. Mr. McCormick's vast experience includes more than 25 years of service in the medical device industry through varying leadership roles for several private and publicly traded companies. Mr. McCormick will also serve as Lead Independent Director and serve as a member of the Audit Committee and as Chair of the Nominating and Corporate Governance Committee of the Board.

Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors

Nuwellis, Inc. (NASDAQ:NUWE ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants Vivian Cervantes - Investor Relations Nestor Jaramillo - President and Chief Executive Officer Lynn Blake - Chief Financial Officer John Kowalczyk - Senior Vice President of Sales & Marketing John Jefferies - Chief Medical Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Anthony Vendetti - Maxim Group Operator Good morning and welcome to the Nuwellis First Quarter 2023 Conference Call. All participants will be in a listen-only mode.

Nuwellis, Inc. (NUWE) Q1 2023 Earnings Call Transcript

MINNEAPOLIS, May 09, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2023.

Nuwellis, Inc. Announces First Quarter 2023 Financial Results

MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of an analysis of available ultrafiltration clinical trials with findings that support ultrafiltration as a safe and effective therapeutic option for acute decompensated heart failure (ADHF) patients who are resistant to diuretics or who have a history of multiple hospitalizations for fluid overload. The publication highlights the scale of clinical burden: “ADHF has the highest rate of hospital readmissions among all medical conditions and portends a significant financial burden on healthcare systems worldwide.”1

Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics

Nuwellis, Inc. (NASDAQ:NUWE ) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO Lynn Blake - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Anthony Vendetti - Maxim Group Brooks O'Neil - Lake Street Capital Markets Operator Good morning, and welcome to the Nuwellis Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded.

Nuwellis, Inc. (NUWE) Q4 2022 Earnings Call Transcript

Q4 Revenue Up 42%; Expansion of Clinical Evidence Sets Stage for 2023 Growth Q4 Revenue Up 42%; Expansion of Clinical Evidence Sets Stage for 2023 Growth

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results

MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo, President and Chief Executive Officer, and Lynn Blake, Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.

Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference

MINNEAPOLIS, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023. The company will host a conference call and webcast at 8:30 AM ET, during which management will discuss the company's financial results and provide a general business overview.

Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced preliminary unaudited results for fourth quarter and full year 2022.

News for Nuwellis Stock (NUWE)